Keystone eSymposia Logo

Cancer Stem Cells: Advances in Biology and Clinical Translation

May 19-21, 2021 | 8:00AM EDT | 12:00PM UTC | 2:00PM CEST*
*Program is in development and subject to change


The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.

 Free Access to On Demand Content to Scientists from Low-and Middle-Income Countries

Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.

Apply Here

Preponderant experimental and clinical evidence has demonstrated that pervasive cancer cell heterogeneity in both phenotypic presentations and functional properties exists, such that a population of cancer cells with cardinal stem cell properties (i.e., cancer stem cells) pre-exists in untreated tumors and spatiotemporally evolves during tumor progression and therapeutic interventions. Recent studies have also revealed significant phenotypic and functional plasticity in cancer cells, regulated by both genetic networks and epigenetic mechanisms. Both cancer cell heterogeneity and plasticity constitute major barriers to effective and durable clinical treatments. 

Ever since the revival of the cancer stem cell research field in the last two decades, we have made great strides in identifying and elucidating the biology of cancer stem cells in virtually all tumor systems. Significant progress has also been made in understanding how cancer stem cells interact with the cellular constituents and soluble factors in the proinflammatory and immune-suppressive tumor microenvironment. Facilitated by an explosion of technical advances in recent years, especially single-cell RNA-seq, we are achieving an unprecedented appreciation of the complexity of the cellular heterogeneity of human tumors. Significantly, novel therapeutic strategies that target cancer stem cells and cancer cell heterogeneity and plasticity are rapidly progressing to the clinical arena. 

This conference is organized to recapitulate these recent advances in our understanding of cancer stem cell biology and, importantly, the clinical translation of targeting cancer stem cells.

Apply Here for Free On Demand Access


Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD


Abstract Submission
‣ For Short Talk Consideration: Passed
‣ For Poster Booth: Passed
ePoster / SciTalk Submission: Passed
Financial Aid Application: Passed

*Abstract submission is required in order to submit an ePoster and/or Scitalk


Program Details

Keynote Speakers


Irving L. Weissman, MD
Stanford University

Speaking at this eSymposia

Anna Dubrovska

University Hospital Carl Gustav Carus, Germany

Markus Grompe

Oregon Health & Science University, USA

Wei Guo

University of Pennsylvania, USA

Junfang Ji

Zhejiang University, China

Klaus H. Kaestner

University of Pennsylvania School of Medicine, USA

Calvin Kuo

Stanford University, USA

Justin D. Lathia

Cleveland Clinic, USA

Stephanie K.Y. Ma

University of Hong Kong, Hong Kong

Jan Joseph Melenhorst

University of Pennsylvania, USA

Irene Oi Lin Ng

University of Hong Kong, Hong Kong

Duanqing Pei

Guangzhou Institutes of Biomedicine and Health, China

Lola McAdams Reid

University of North Carolina at Chapel Hill, USA

Clemens A. Schmitt

Max Delbrück Center for Molecular Medicine, Germany

Michael M. Shen

Columbia University, USA

Erwei Song

Sun-Yat-Sen Memorial Hospital, China

Dean G. Tang

Roswell Park Cancer Institute, USA

Xin Wei Wang

NCI, National Institutes of Health, USA

Irving L. Weissman

Stanford University, USA

Richard White

Memorial Sloan Kettering Cancer Center, USA

Wolf Ruprecht Wiedemeyer

AbbVie, Inc., USA

Carmen Chak-Lui Wong

University of Hong Kong, Hong Kong

Chunzhang Yang

NCI, National Institutes of Health, USA

Ning Zhang

Peking University, China





Additional Support




Funding for this conference was made possible (in part) by 1R13CA261003-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Media-in-Kind Support










Additional in-Kind Support



The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.


This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community.  Here, Debbie Johnson, our CEO, explains how we're going to do that.

Donate to Keystone Symposia

Donate to Keystone Symposia